Ocular Survival Following Intravitreal Melphalan as Adjuvant Treatment for Vitreous Retinoblastoma Seeding

References

• González ME, Gaviria ML, López M, Escudero PA, Bravo A, Vargas SA. Eye Salvage with Intra-Arterial and Intra-Vitreal Chemotherapy in Patients with Retinoblastoma: 8-Year Single-Institution Experience in Colombia. Ocular Oncol Pathol. 2021;7(3):215–223. doi:10.1159/000511980
   PubMed Web of Science ®Google Scholar
• Abramson DH, Ji X, Francis JH, Catalanotti F, Brodie SE, Habib L. Intravitreal chemotherapy in retinoblastoma: expanded use beyond intravitreal seeds. Br J Ophthalmol. 2019;103(4):488–493. doi:10.1136/bjophthalmol-2018-312037
   PubMed Web of Science ®Google Scholar
• Ancona-Lezama D, Dalvin L, Shields C. Modern treatment of retinoblastoma: a 2020 review. Indian J Ophthalmol. 2020;68(11):2356. doi:10.4103/ijo.IJO_721_20
   PubMed Web of Science ®Google Scholar
• Shields CL, Manjandavida FP, Arepalli S, Kaliki S, Lally SE, Shields JA. Intravitreal melphalan for persistent or recurrent retinoblastoma vitreous seeds: preliminary results. JAMA Ophthalmol. 2014;132(3):319–325. doi:10.1001/jamaophthalmol.2013.7666
   PubMed Web of Science ®Google Scholar
• Ghassemi F, Shields CL. Intravitreal melphalan for refractory or recurrent vitreous seeding from retinoblastoma. Arch Ophthalmol. 2012;130(10):1268. doi:10.1001/archophthalmol.2012.1983
   PubMedGoogle Scholar
• Francis JH, Marr BP, Brodie SE, Gobin P, Dunkel IJ, Abramson DH. Intravitreal melphalan as salvage therapy for refractory retinal and subretinal retinoblastoma. Retin Cases Brief Rep. 2016;10(4):357–360. doi:10.1097/ICB.0000000000000262
   PubMedGoogle Scholar
• Kaneko A. Eye-preservation treatment of retinoblastoma with vitreous seeding. Jpn J Clin Oncol. 2003;33(12):601–607. doi:10.1093/jjco/hyg113
   PubMed Web of Science ®Google Scholar
• Munier FL, Gaillard MC, Balmer A, et al. Intravitreal chemotherapy for vitreous disease in retinoblastoma revisited: from prohibition to conditional indications. Br J Ophthalmol. 2012;96(8):1078–1083. doi:10.1136/bjophthalmol-2011-301450
   PubMed Web of Science ®Google Scholar
• Shields CL, Fulco EM, Arias JD, et al. Retinoblastoma frontiers with intravenous, intra-arterial, periocular, and intravitreal chemotherapy. Eye. 2013;27(2):253–264. doi:10.1038/eye.2012.175
   PubMed Web of Science ®Google Scholar
• Smith SJ, Smith BD. Evaluating the risk of extraocular tumour spread following intravitreal injection therapy for retinoblastoma: a systematic review. Br J Ophthalmol. 2013;97(10):1231–1236. doi:10.1136/bjophthalmol-2013-303188
   PubMed Web of Science ®Google Scholar
• General Authority for Statistics, Kingdom of Saudi Arabia. Data [Webpage title]. Saudi Census, 2022. Available from: https://www.stats.gov.sa/en/statistics-overview. Accessed 30, December 2022.
   Google Scholar
• Shields CL, Mashayekhi A, Au AK, et al. The international classification of retinoblastoma predicts chemoreduction success. Ophthalmology. 2006;113(12):2276–2280. doi:10.1016/j.ophtha.2006.06.018
   PubMed Web of Science ®Google Scholar
• Munier FL. Classification and Management of Seeds in RetinoblastomaEllsworth Lecture Ghent August 24th 2013. Ophthalmic Genet. 2014;35(4):193–207. doi:10.3109/13816810.2014.973045
   PubMed Web of Science ®Google Scholar
• Berry JL, Bechtold M, Shah S, et al. Not all seeds are created equal: seed classification is predictive of outcomes in retinoblastoma. Ophthalmology. 2017;124(12):1817–1825. doi:10.1016/j.ophtha.2017.05.034
   PubMed Web of Science ®Google Scholar
• Munier FL, Beck-Popovic M, Chantada GL, et al. Conservative management of retinoblastoma: challenging orthodoxy without compromising the state of metastatic grace. “Alive, with good vision and no comorbidity. Prog Retin Eye Res. 2019;73:100764. doi:10.1016/j.preteyeres.2019.05.005
   PubMed Web of Science ®Google Scholar
• Berry JL, Kim ME, Pefkianaki M, et al. Intravitreal melphalan for retinoblastoma: the impact of toxicity on recurrence and ultimate globe salvage. Ocul Oncol Pathol. 2020;6(6):388–394. doi:10.1159/000509080
   PubMed Web of Science ®Google Scholar
• Yousef YA, Noureldin AM, Sultan I, et al. Intravitreal melphalan chemotherapy for vitreous seeds in retinoblastoma. J Ophthalmol. 2020;2020:1–7. doi:10.1155/2020/8628525
   Web of Science ®Google Scholar
• Kiratli H, İ K, Varan A, Akyüz C. Intravitreal chemotherapy in the management of vitreous disease in retinoblastoma. Eur J Ophthalmol. 2017;27(4):423–427. doi:10.5301/ejo.5000921
   PubMed Web of Science ®Google Scholar
• Francis JH, Abramson DH, Ji X, et al. Risk of extraocular extension in eyes with retinoblastoma receiving intravitreous chemotherapy. JAMA Ophthalmol. 2017;135(12):1426–1429. doi:10.1001/jamaophthalmol.2017.4600
   PubMed Web of Science ®Google Scholar
• Rishi P, Sharma T, Agarwal V, et al. Complications of intravitreal chemotherapy in eyes with retinoblastoma: see editorial on pg. 359. Oph Retina. 2017;1(5):448–450. doi:10.1016/j.oret.2017.03.006
   PubMedGoogle Scholar
• Paysse EA, Miller A, Brady McCreery KM, Coats DK. Acquired cataracts after diode laser photocoagulation for threshold retinopathy of prematurity. Ophthalmology. 2002;109(9):1662–1665. doi:10.1016/s0161-6420(02)01169-7
   PubMed Web of Science ®Google Scholar
• Xue K, Ren H, Meng F, Zhang R, Qian J. Ocular toxicity of intravitreal melphalan for retinoblastoma in Chinese patients. BMC Ophthalmol. 2019;19(1):61. doi:10.1186/s12886-019-1059-4
   PubMedGoogle Scholar
• Narala R, Kim JW, Lang P, et al. Changes in Retinal Thickness on OCT from Intravitreal Melphalan. Ophthalmology Retina. 2019;3(3):288–289. doi:10.1016/j.oret.2018.09.020
   PubMedGoogle Scholar
• Francis JH, Brodie SE, Marr B, Zabor EC, Mondesire-Crump I, Abramson DH. Efficacy and toxicity of intravitreous chemotherapy for retinoblastoma: four-year experience. Ophthalmology. 2017;124(4):488–495. doi:10.1016/j.ophtha.2016.12.015
   PubMed Web of Science ®Google Scholar
• Ji X, Hua P, Li J, Li J, Zhao J, Zhao P. Intravitreal melphalan for vitreous seeds: initial experience in China. J Ophthalmol. 2016;2016:1–7. doi:10.1155/2016/4387286
   Web of Science ®Google Scholar
• Berry JL, Shah S, Bechtold M, Zolfaghari E, Jubran R, Kim JW. Long-term outcomes of Group D retinoblastoma eyes during the intravitreal melphalan era. Pediatr Blood Cancer. 2017;64(12):e26696. doi:10.1002/pbc.26696
   Web of Science ®Google Scholar
• Solana-Altabella A, Valero S, Balaguer J, et al. Intravitreal melphalan therapy for vitreous seeds in retinoblastoma: implementation and outcomes of a new chemotherapy protocol. J Oncol Pharm Pract. 2020;26(8):1829–1835. doi:10.1177/1078155220904410
   PubMed Web of Science ®Google Scholar
• Gündüz AK, Mirzayev I, Dinçaslan H, Özalp Ateş FS. Recurrence and new tumor development after frontline intravenous chemotherapy for retinoblastoma: risk factors and treatment results. Eur J Ophthalmol. 2022;32(3):1795–1803. doi:10.1177/11206721211023311
   PubMed Web of Science ®Google Scholar
• Dalvin LA, Bas Z, Tadepalli S, et al. Risk Factors for Tumor Recurrence Following Primary Intravenous Chemotherapy (Chemoreduction) for Retinoblastoma in 869 Eyes of 551 Patients. J Pediatr Ophthalmol Strabismus. 2020;57(4):224–234. doi:10.3928/01913913-20200417-01
   PubMed Web of Science ®Google Scholar
• Smith SJ, Smith BD, Mohney BG. Ocular side effects following intravitreal injection therapy for retinoblastoma: a systematic review. Br J Ophthalmol. 2014;98(3):292–297. doi:10.1136/bjophthalmol-2013-303885
   PubMed Web of Science ®Google Scholar
• Shields CL, Dockery PW, Yaghy A, et al. Intra-arterial chemotherapy for retinoblastoma in 341 consecutive eyes (1292 infusions): comparative analysis of outcomes based on patient age, race, and sex. J AAPOS. 2021;25(3):150.e1–150.e9. doi:10.1016/j.jaapos.2020.12.006
   Web of Science ®Google Scholar
• Mirzayev I, Gündüz AK, Yavuz K, et al. Secondary intra-arterial chemotherapy and/or intravitreal chemotherapy as salvage treatment for retinoblastoma. Eur. J Ophthalmol. 2021;31(5):2692–2698. doi:10.1177/1120672120957587
   Web of Science ®Google Scholar
• Sims LB, Tyo KM, Stocke S, Mahmoud MY, Ramasubramanian A, Steinbach-Rankins JM. Surface-modified melphalan nanoparticles for intravitreal chemotherapy of retinoblastoma. Invest Ophthalmol Vis Sci. 2019;60(5):1696. doi:10.1167/iovs.18-26251
   PubMed Web of Science ®Google Scholar
• Nadelmann J, Francis JH, Brodie SE, Muca E, Abramson DH. Is intravitreal topotecan toxic to retinal function? Br J Ophthalmol. 2021;105(7):1016–1018. doi:10.1136/bjophthalmol-2020-316588
   PubMed Web of Science ®Google Scholar